Cytotoxicity of Low Dose Epirubicin-HCl Combined with Lymphokine Activated Killer Cells Against Hepatocellular Carcinoma Cell Line Hepatoma G2

Turkish Journal of Medical Sciences

Volumn 34, Issue 1, 2004, Pages 11-19

  Özkan, Aysun ^a   Fişkin, Kayahan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Cytotoxicity; Enzymes; Epirubicin HCl; Hepatoma

Indexed keywords

ANTIBIOTICS; ANTIOXIDANTS; CATALYSTS; CELLS; ELECTRONS; ENZYMES; HYDROCHLORIC ACID; SYNTHESIS (CHEMICAL); TOXICITY; TUMORS;

EFFECTOR CELLS; OXYRADICAL GENERATION;

BIOMEDICAL ENGINEERING;

ANTINEOPLASTIC ANTIBIOTIC; CATALASE; CYTOCHROME P450 REDUCTASE; EPIRUBICIN; GLUTATHIONE PEROXIDASE; NITRIC OXIDE; OXYGEN RADICAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SCAVENGER;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; EFFECTOR CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPHOKINE ACTIVATED KILLER CELL; PROTEIN EXPRESSION; TARGET CELL;

EID: 1542375891     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Trinchieri G. Biology of natural killer cells. Adv. Immunol 47: 187-190, 1989.
2. 2 and EDTA. J Immun Methods 41: 121-129, 2000.
3. Kwak, JY, Han MK, Choi KS et al. Cytokines secreted by lymhokine-activated killer cells induced endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell Immunol, 203: 84-94, 2000.
4. Synder HS, Bredt DS. Biological roles of nitric oxide. Scientific American 5: 28-34, 1992.
5. Dobbs NA, Twelwes CJ, Rizzi P et al. Epirubicin-HCl in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemotherapy and Pharmacology, 34: 405-410, 1994.
6. Glisson BS, Ross WE. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmaco Therapy 32, 89-106, 16, 1987.
7. Bachur NR, Gee MV, Friedman RD. Nuclear-catalysed antibiotic free radical formation. Cancer Res 42: 1078-1081, 1982.
8. Lind C, Hocgstein P, Ernster L. DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys 216: 178-185, 1982
9. Kappus H. Overview of enzyme system involved in bioreduction of drugs and in redox cycling. Biochem Pharmacol 35: 12419-12425, 1986.
10. Haniu M, McManus E, Donald J, Birkett DJ et al. Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites. Biochem 28: 8639-8645, 1989.
11. Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol 27: 251-255, 1997.
12. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320, 1994.
13. Pross HF, Baines MG, Rubin P et al. Spontaneous human lymphocyte-mediated cytotoxicity against tumour target cells. IX. Quantitation of natural killer cell activity. J Clin Immunol 1: 51-63, 1981.
14. Grimm E. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823-1841, 1982.
15. Heo DS, Park J-G, Hata K et al. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 50: 3681-3688, 1990.
16. Hussain RF, Nouri AME, Oliver RTD. A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160: 89-93, 1993.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods: 65, 55-63, 1983.
18. Carlberg I, Mannervik B. Glutathione reductase. Methods Enzymol 113: 448-490, 1985.
19. Habig WH, Jakoby WB. Assay for differentiation of glutathione S-transferases. Methods in Enzymol 77: 398-405, 1974.
20. McCord JM, Fridovich IJ. Preparation and assays of superoxide dismutase. Biol Chem 244: 6049-6055, 1969.
21. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterisation of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158-169, 1967.
22. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium deficient rat liver. Biochem Biophys Res Com 71: 952-958, 1976.
23. Luck H. Catalase. In H.U. Bergmeyer (ed.), Methods of Enzymatic Analayses, Verlag chemie Academic Press, Weinheim, New York. 1963, pp 885-888.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Annal Biochem 72: 248-254, 1976.
25. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: A laboratory manual. N. Y., 1982 Cold Spring Harbor Laboratory, 221-242.
26. th ed. Ames, Iowa U.S.A. 1967, Iowa State University Press, 162-171.
27. Duncan, D.B. (1955). Multiple Range and Multiple F Test. Biometrics, U.S.A. 1955, 11: 1-14.
28. Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection hepatocellular carcinoma - A literature review of randomised control trials. World J Gastroenterol 9: 635-640, 2003.
29. Sinha BK. Free radicals in anticancer drug pharmacology. Chem Biol Interact 69: 293-317, 1989.
30. Komatsu F, Ishiguro K. Lymphokine-activated killer cells can kill target cells not only early killing but also by late killing, and the late killing level against autotumor cell line. Oncol Res 13: 235-241, 2003.
31. Rihova B, Strohalm J, Kubackova K et al. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J Control Release 17: 97-114, 2002.
32. Grunberg E, Eckert K, Maurer HR. Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro. Int J Oncol 12: 957-963, 1998.
33. Matsuzaki I, Suzuki H, Kitamura M et al. Cisplatin induces Fas expression in esophageal cancer cell lines and enhanced cytotoxicity in conbination with LAK cells. Oncology 59: 336-343, 2000.
34. Chen R, Pan L, Zhou S. Cytotoxicities of low dose anticancer agents combining lymphokine activated killer cell against ovarian adenocarcinoma cell line SKOV3. Zhonghua Fu Chan Ke Za Zhi, 34: 172-174, 1999.
35. Okamoto M, Kasetani H, Kaji R et al. Cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother 4: 233-241, 1998.
36. Wolfram ES, Ryan P, Salvatore C et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med 9: 750-755, 2003.
37. Kinnula K, Linnainma K, Raivio KO et al. Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. Br J Cancer 77: 1097-1102, 1998.
38. Yamamota T, Yoneda K, Ueta E et al. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. Eur J Cancer. 36: 2007-2017, 2000.
39. Kohno K, Sato S, Takano H et al. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Comm 165: 1415-1421, 1989.
40. Joncourt F, Buser K, Bacchi M et al. Multiple drug resistance parameter in ovarian cancer. Gynecol Oncol 70: 176-182, 1998.
41. Runge D, Köhler C, Kostrubsky EV et al. Reduction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-19 by prototypical reducers in human hepatocytes. Biochem Biophys Res Com 273: 333-341, 2000.
42. Dierickx PJ. Glutathione-dependent cytotoxicity of the chloroacetanilide herbicides alachlor, metolachor, and propachlor in rat and human hepatoma-derived cultured cells. Cell Biol. Toxicol 15: 325-332, 1999.